Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating genetically engineered MUC1-activated T-cells for treating recurrent or refractory multiple myeloma, spons…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]
Open-label Phase 3 trial comparing Iberdomide with Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone …
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating BCMA-directed CAR-T cell therapy in adults with multiple myeloma was terminated.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase 1 clinical trial of IMV102 for relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [Phase 2]
Phase 2 study evaluating a quadruplet regimen of isatuximab, pomalidomide, elotuzumab, and dexamethasone for relapsed/refractory multiple my…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update discusses response-based dose reduction of Linvoseltamab in relapsed/refractory multiple myeloma across Phase 1 a…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]
Phase 1 safety and tolerability study of CFT7455 in relapsed/refractory non-Hodgkin's lymphoma and multiple myeloma is currently active but …
-
CLINICAL_TRIALS trial_result · 2026-03-24Clinical Trial Update: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Enzomenib (DSP-5336) for acute leukemias, including acute myeloid leukemia and acute lymphoblastic leu…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma [Phase 2]
Phase 2 study evaluating belantamab mafodotin as pre- and post-autologous stem cell transplant and maintenance therapy for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) [Phase 2]
Phase 2 MATCH subprotocol update assessing crizotinib for cancers with MET exon 14 deletions; results have been posted (2026-03-20).
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma [Phase 1, Phase 2]
Results from a Phase 1/2 study of CC-220 (iberdomide) as monotherapy and in combination for multiple myeloma, focusing on dose, safety, tole…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) [Phase 2]
A Phase 2 MATCH subprotocol evaluating crizotinib for cancers with MET genetic alterations; results have been posted for this study.
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
This Phase 1 study assesses the safety, pharmacokinetics, and preliminary activity of Cevostamab in participants with relapsed or refractory…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial of ECT-001 (UM171) expanded cord blood transplant for high-risk multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating daratumumab in transplant-eligible patients with multiple myeloma has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: EHealth Educational Intervention to Improve Self-Management and Coping Behaviors Among Cancer Patients [NA]
A completed clinical trial evaluating an eHealth educational intervention to improve self-management and coping behaviors among cancer patie…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma [Phase 2]
This is a Phase 2 clinical trial of a personalized Selinexor-based therapy for relapsed/refractory multiple myeloma. The results have been p…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders [NA]
This update reports the completed status of a trial assessing bone marrow and kidney transplant for patients with chronic kidney disease and…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse [Phase 2]
A Phase 2 trial investigating daratumumab as first-line therapy in transplant-ineligible multiple myeloma patients, with possible daratumuma…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma [Phase 2]
Phase 2 study evaluating the efficacy and safety of bb2121 in relapsed/refractory and high-risk multiple myeloma has completed, with reporte…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: A Study of Ninlaro in Real World Clinical Practice in China
A completed real-world study evaluating Ninlaro (ixazomib) in Chinese clinical practice for multiple myeloma. The study analyzes how the dru…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 [Phase 1]
Long-term follow-up data are being collected for subjects treated with P-BCMA-101 in a Phase 1 study for multiple myeloma. The trial status …
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating response-adapted initial therapy for multiple myeloma using bortezomib/dexamethasone, with lenalidomide added for n…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Biomarkers of AKI in Patients Receiving Daratumumab
A completed clinical trial update investigating biomarkers of acute kidney injury in patients treated with daratumumab for multiple myeloma,…
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment [Phase 1]
This document updates a Phase 1 clinical trial evaluating belantamab mafodotin in combination with nirogacestat and pomalidomide for relapse…